HCW Biologics Inc. (NASDAQ:HCWB) Stock Short Interest Report for September

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 60,941 shares, a growth of 557.1% from the September 15th total of 9,274 shares. Based on an average daily trading volume, of 1,348,961 shares, the days-to-cover ratio is presently 0.0 days. Approximately 3.0% of the shares of the company are short sold.

HCW Biologics Stock Up 4.6%

HCW Biologics stock traded up $0.07 during trading hours on Friday, hitting $1.60. 79,948 shares of the company traded hands, compared to its average volume of 772,095. HCW Biologics has a 1-year low of $1.50 and a 1-year high of $27.57. The firm has a market cap of $3.58 million, a P/E ratio of -0.06 and a beta of 2.41. The firm’s 50-day simple moving average is $2.45 and its two-hundred day simple moving average is $4.19.

HCW Biologics (NASDAQ:HCWB) last issued its quarterly earnings results on Friday, August 14th. The company reported ($11.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). The company had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.14 million. HCW Biologics had a negative return on equity of 262.33% and a negative net margin of 83.03%.

Analysts Set New Price Targets

Several brokerages have weighed in on HCWB. Wall Street Zen downgraded HCW Biologics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, HCW Biologics has a consensus rating of “Hold” and an average price target of $30.00.

HCW Biologics Company Profile

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases.

HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic.